Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cancer

Many clinical trials are being conducted to clarify effective combinations of various drugs for immune checkpoint blockade (ICB) therapy. However, although extensive studies from multiple aspects have been conducted regarding treatments for pancreatic ductal adenocarcinoma (PDAC), there are still no...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashimoto, Ari, Handa, Haruka, Hata, Soichiro, Tsutaho, Akio, Yoshida, Takao, Hirano, Satoshi, Hashimoto, Shigeru, Sabe, Hisataka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127265/
https://www.ncbi.nlm.nih.gov/pubmed/34001163
http://dx.doi.org/10.1186/s12964-021-00733-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127265/
https://www.ncbi.nlm.nih.gov/pubmed/34001163
http://dx.doi.org/10.1186/s12964-021-00733-y

Ejemplares similares